Alejandro Pérez Cabeza

Safety of the oral factor XIa inhibitor asundexian compared with apixaban in patients with atrial fibrillation (PACIFIC-AF): a multicentre, randomised, double-blind, double-dummy, dose-finding phase 2 study

Jonathan P. Piccini, Valeria Caso, Stuart J. Connolly et al. · The Lancet · 2022 · 296 citations · Full text

Thrombosis, Dose-finding Phase 2, Cardiovascular Disease +10

Natural History of MYH7-Related Dilated Cardiomyopathy

Fernando de Frutos, Juan Pablo Ochoa, Marina Navarro Peñalver et al. · Journal of the American College of Cardiology · 2022 · 83 citations · Full text

Dynamic Left Ventricular Outflow Tract Obstruction Induced by Exercise

Fernando Cabrera Bueno, Isabel Rodríguez Bailón, Raúl López Salguero et al. · Revista Española de Cardiología (English Edition) · 2004 · 24 citations

Heart Failure, Kinesiology, Cardiac Mechanic +9

Changes in serum and cerebrospinal fluid enzyme activity after head injury

G. Fl�rez, Alejandro Pérez Cabeza, J.M. Morales González et al. · Acta Neurochirurgica · 1976 · 19 citations

Neurophysiology, Medicine, Cerebrospinal Fluid +10

Thromboembolic and bleeding events with rivaroxaban in clinical practice in Spain: impact of inappropriate doses (the EMIR study)

Marcelo Sanmartı́n, Carles Ràfols, Fernando Arribas et al. · Journal of Comparative Effectiveness Research · 2021 · 17 citations